Skip to main content
Top
Published in: Annals of Hematology 4/2021

01-04-2021 | Multiple Myeloma | Review Article

Risk factors for monoclonal gammopathy of undetermined significance: a systematic review

Authors: Maira A. Castaneda-Avila, Christine M. Ulbricht, Mara Meyer Epstein

Published in: Annals of Hematology | Issue 4/2021

Login to get access

Abstract

Monoclonal gammopathy of undetermined significance (MGUS), precursor of multiple myeloma, is an asymptomatic plasma cell disorder that overproduces serum monoclonal protein. Older age, male sex, black race, and family history of MGUS increase the risk of MGUS, yet other risk factors are known. We systematically reviewed observational epidemiological studies that examined sociodemographic, clinical, and behavioral risk factors for the development of MGUS. The protocol for this study was registered on the PROSPERO registry for systematic reviews. We identified epidemiological studies from PubMed and Scopus. Articles were limited to those written in English and published before February 2019. Five case-control and three cohort studies were eligible for data extraction. Studies evaluating factors associated with MGUS risk are limited, with conflicting conclusions regarding risk associated with obesity. Despite the limited research, a significant elevated risk for being diagnosed with MGUS was associated with several specific prior infections, inflammatory disorders, and smoking. The sparse existing literature suggests an increased risk of MGUS associated with several risk factors related to immune function. Further research is needed to explore the potential mechanisms underlying the development of MGUS and to confirm risk factors, both modifiable and non-modifiable.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kyle RA, Rajkumar SV (2003) Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 194:112–139CrossRef Kyle RA, Rajkumar SV (2003) Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 194:112–139CrossRef
2.
go back to reference Merlini G, Palladini G (2012) Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012:595–603CrossRef Merlini G, Palladini G (2012) Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program 2012:595–603CrossRef
4.
go back to reference Landgren O et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–5417CrossRef Landgren O et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–5417CrossRef
5.
go back to reference Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418–5422CrossRef Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418–5422CrossRef
6.
go back to reference Goldin LR, McMaster ML, Caporaso NE (2013) Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomark Prev 22:533–539CrossRef Goldin LR, McMaster ML, Caporaso NE (2013) Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomark Prev 22:533–539CrossRef
7.
go back to reference Zingone A, Kuehl WM (2011) Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 48:4–12CrossRef Zingone A, Kuehl WM (2011) Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol 48:4–12CrossRef
8.
go back to reference Wadhera RK, Rajkumar SV (2010) Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 85:933–942CrossRef Wadhera RK, Rajkumar SV (2010) Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc 85:933–942CrossRef
9.
go back to reference Kyle RA et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369CrossRef Kyle RA et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369CrossRef
10.
go back to reference Landgren O et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468–1473CrossRef Landgren O et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468–1473CrossRef
11.
go back to reference Landgren O et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906CrossRef Landgren O et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906CrossRef
12.
go back to reference Landgren O et al (2009) Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114:791–795CrossRef Landgren O et al (2009) Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114:791–795CrossRef
13.
go back to reference McShane CM et al (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol Biomark Prev 23:332–342CrossRef McShane CM et al (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol Biomark Prev 23:332–342CrossRef
14.
go back to reference Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359–5366CrossRef Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359–5366CrossRef
15.
go back to reference Kristinsson SY et al (2009) Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 94:1714–1720CrossRef Kristinsson SY et al (2009) Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 94:1714–1720CrossRef
16.
go back to reference Kyle RA et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569CrossRef Kyle RA et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569CrossRef
17.
go back to reference Gregersen H et al (2010) Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. Eur J Intern Med 21:564–568CrossRef Gregersen H et al (2010) Survival of cancer patients with prior monoclonal gammopathy of undetermined significance. Eur J Intern Med 21:564–568CrossRef
18.
go back to reference Gregersen H et al (2001) Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 112:353–357CrossRef Gregersen H et al (2001) Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. Br J Haematol 112:353–357CrossRef
19.
go back to reference Atkin C, Richter A, Sapey E (2018) What is the significance of monoclonal gammopathy of undetermined significance? Clin Med 18:391–396CrossRef Atkin C, Richter A, Sapey E (2018) What is the significance of monoclonal gammopathy of undetermined significance? Clin Med 18:391–396CrossRef
20.
go back to reference Berenson JR et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28–38PubMed Berenson JR et al (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28–38PubMed
21.
go back to reference Maiese E, Evans K, Chu B-C, Irwin DE (2017) Trends in survival and costs among U.S. patients with multiple myeloma. J Clin Oncol 35:12–12CrossRef Maiese E, Evans K, Chu B-C, Irwin DE (2017) Trends in survival and costs among U.S. patients with multiple myeloma. J Clin Oncol 35:12–12CrossRef
22.
go back to reference Moher D et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1CrossRef Moher D et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1CrossRef
23.
go back to reference Booth A et al (2012) The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 1:2CrossRef Booth A et al (2012) The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev 1:2CrossRef
24.
go back to reference Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384CrossRef Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384CrossRef
25.
go back to reference Hajduk AM, Kiefe CI, Person SD, Gore JG, Saczynski JS (2013) Cognitive change in heart failure: a systematic review. Circ Cardiovasc Qual Outcomes 6:451–460CrossRef Hajduk AM, Kiefe CI, Person SD, Gore JG, Saczynski JS (2013) Cognitive change in heart failure: a systematic review. Circ Cardiovasc Qual Outcomes 6:451–460CrossRef
26.
go back to reference Boursi B, Weiss BM, Haynes K, Mamtani R, Yang Y-X (2016) Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. Am J Hematol 91:581–584CrossRef Boursi B, Weiss BM, Haynes K, Mamtani R, Yang Y-X (2016) Reappraisal of risk factors for monoclonal gammopathy of undetermined significance. Am J Hematol 91:581–584CrossRef
27.
go back to reference Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394CrossRef Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394CrossRef
28.
go back to reference Landgren O et al (2010) Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 116:1056–1059CrossRef Landgren O et al (2010) Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 116:1056–1059CrossRef
29.
go back to reference Lindqvist EK et al (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291CrossRef Lindqvist EK et al (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291CrossRef
30.
go back to reference Pasqualetti P, Collacciani A, Casale R (1996) Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol 52:217–220CrossRef Pasqualetti P, Collacciani A, Casale R (1996) Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am J Hematol 52:217–220CrossRef
31.
go back to reference Pasqualetti P et al (1997) Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol 97:659–662CrossRef Pasqualetti P et al (1997) Tobacco smoking and risk of haematological malignancies in adults: a case-control study. Br J Haematol 97:659–662CrossRef
32.
go back to reference Thordardottir M et al (2017) Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv 1:2186–2192CrossRef Thordardottir M et al (2017) Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv 1:2186–2192CrossRef
33.
go back to reference Thordardottir M et al (2018) Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS One 13:e0206047CrossRef Thordardottir M et al (2018) Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS One 13:e0206047CrossRef
34.
go back to reference Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638CrossRef Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638CrossRef
35.
go back to reference Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578CrossRef Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578CrossRef
36.
go back to reference Blak BT, Thompson M, Dattani H, Bourke A (2011) Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19:251–255PubMed Blak BT, Thompson M, Dattani H, Bourke A (2011) Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 19:251–255PubMed
37.
go back to reference Andreotti G et al (2015) A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium. Cancer Epidemiol Biomark Prev 24:631–634CrossRef Andreotti G et al (2015) A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium. Cancer Epidemiol Biomark Prev 24:631–634CrossRef
38.
go back to reference Genkinger JM et al (2015) Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol 26:2257–2266CrossRef Genkinger JM et al (2015) Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Ann Oncol 26:2257–2266CrossRef
39.
go back to reference Landgren O et al (2017) Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J 7:e618CrossRef Landgren O et al (2017) Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J 7:e618CrossRef
40.
go back to reference Epstein MM et al (2020) Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf 29:69–76CrossRef Epstein MM et al (2020) Identifying monoclonal gammopathy of undetermined significance in electronic health data. Pharmacoepidemiol Drug Saf 29:69–76CrossRef
Metadata
Title
Risk factors for monoclonal gammopathy of undetermined significance: a systematic review
Authors
Maira A. Castaneda-Avila
Christine M. Ulbricht
Mara Meyer Epstein
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 4/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-021-04400-7

Other articles of this Issue 4/2021

Annals of Hematology 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.